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Abstract
Objective: To assess the association between Parkinson’s disease (PD) and melanoma via systematic review and
meta-analysis.
Methods: Comprehensive search in PubMed, Web of Science, Embase and four China databases (SinoMed,
WanFang data, CNKI and VIP database) of epidemiologic evidences on PD and melanoma published before April
30, 2015. Studies which reported risk estimates of melanoma among PD patients or risk estimates of PD in patients
with melanoma were included. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated by
random-effects models. Heterogeneity across studies was assessed using Cochran Q and I2 statistics. Subgroup
analyses and sensitivity analyses were conducted to evaluate sources of heterogeneity. Subgroup analyses were
done according to temporal relationship, geographic region and gender respectively. We assessed publication bias
using the Begg and Egger test. In addition, study appraisal was done using a scale for observational studies to
ensure the quality of evidence.
Results: We identified 24 eligible studies on PD and melanoma with a total number of 292,275 PD patients: the
pooled OR was 1.83 (95 % CI 1.46–2.30) overall, subgroup analyses by temporal relationship showed that risk of
melanoma after PD diagnosis was significantly higher (OR 2.43, 95 % CI 1.77–3.32), but not before the diagnosis of
PD (OR 1.09, 95 % CI 0.78–1.54). Subgroup analysis by geographic region showed that increased risk of melanoma
in PD was found both in Europe (OR 1.44, 95 % CI 1.22–1.70) and in North America (OR 2.64, 95 % CI 1.63–4.28).
Gender-specific subgroup analyses did not show difference between men (OR 1.64, 95 % CI 1.27–2.13) and women
(OR 1.38, 95 % CI 1.04–1.82) in the risk of melanoma. In addition, we found the risk of non-melanoma skin cancers
in PD was slightly higher (OR 1.20, 95 % CI 1.11–1.29) than general population. It was impossible to evaluate the
association between PD and melanoma according to use of levodopa or gene polymorphism via meta-analysis
since few observational or cohort studies have focused on it.
Conclusions: An association between PD and melanoma was confirmed. Most of the evidences were of high
quality, and the conclusion was robust. Further research is needed to explore the mechanisms underlying this
relationship.
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Introduction
A growing number of evidences suggest that people
with Parkinson’s disease (PD) have a decreased risk of
almost all cancers [1–3]. However, the incidence of
melanoma is strikingly higher in patients with PD
than that in general population [4–6]. Some case re-
ports have linked the use of levodopa (L-dopa) with
the occurrence of malignant melanoma [7, 8], while
some reviews reported that there was apparently no
effect of L-dopa on the risk for malignant melanoma
[9, 10]. The underlying mechanism that link PD with
melanoma is not clear, but it has aroused lots of
interests.
The epidemiology of melanoma focus on well-
known risk factors, such as skin color, hair color, gen-
der and eye pigmentation, moreover, ultraviolet (UV)
exposure is also a risk factor for melanoma [11].
White population is considered to have higher preva-
lence of melanoma than the dark population and the
prevalence is higher in men than in women [11, 12].
Considering the varieties of the reported studies in
study design, patient characteristics and geographical
region, the discrepancy in the results may be related
to insufficient statistical power of individual studies.
Here we conducted a systematic review and meta-
analysis to evaluate the relationship between PD and
melanoma. We also evaluated the non-melanoma skin
cancer risk ratio among patients with PD. Subgroup
analyses with regard to temporal relationship between
PD and melanoma diagnosis, geographic region and
gender were also done.
Methods
Search strategy
We conducted a systematica search of the published ori-
ginal studies that reported the association between skin
cancers and PD. We searched PubMed, Web of Science,
Embase and four China databases (SinoMed, WanFang
data, CNKI and VIP database) for literature published
before April 30, 2015. We combined medical subject
heading (MeSH) terms including “PD, Melanoma, Skin
Neoplasms”, “Carcinoma, Basal Cell” “Carcinoma, Squa-
mous Cell” and “Keratosis, Actinic” and text terms includ-
ing “Parkinson disease, Parkinsons disease, Parkinson’s
disease, melanoma*, skin neoplasm*, basal cell carcinoma,
squamous cell carcinoma, actinic keratosis and skin can-
cer*” as search strategy. Restrictions were made to obser-
vational epidemiologic studies involving humans.
Eligibility criteria
Studies were included if they reported an estimate of as-
sociation between PD and melanoma, e.g. relative risk
(RR), odds ratio (OR), standardized incidence ratio/event
ratio (SIR/SER) with 95 % confidence intervals (CIs) or
data sufficient to calculate them. Then studies in the
form of case report, review, meta-analysis and meeting
abstract were excluded. Next we evaluated the potential
studies by screening titles and abstracts and the refer-
ence lists of all the articles to find other relevant articles
and to further exclude unqualified studies. In details,
two of the coauthors PH and XDY independently evalu-
ated the study titles and abstracts, and disagreements in
the study selection were discussed among the coauthors
until consensus was reached. Also duplicate counting of
events was carefully avoided.
Data extraction and classification
Two of the coauthors PH and XDY independently
searched the literature and extracted the relevant infor-
mation [see Additional file 1] including: name of first au-
thor, study data, study design, sample size, patient
characteristics, geographical region, adjusted risk esti-
mates with corresponding 95 % CIs and other relevant
study characteristics. Attempts were made to contact au-
thors to obtain gender-specific ORs and 95 % CIs if they
were not provided in the original publications. Disagree-
ments were resolved by consensus.
Subgroup analyses were performed according to
temporal relationship between PD and melanoma
diagnosis (study design), geographical region and gen-
der. We also evaluated the relationship between non-
melanoma skin cancers and PD.
Assessment of study quality
Two of the coauthors PH and XDY independently
scored each study [see Additional file 2] according to the
following five criteria items [13]: 1) definition of PD
diagnosis (clearly defined using generally accepted cri-
teria; less well-defined with partial use of generally ac-
cepted criteria; other or no criteria applied; with scores
of 2, 1, 0, respectively); 2) validation of PD diagnosis
(confirmed by neurological exam; confirmed by chart re-
view; no attempt to validate; with scores of 2, 1, 0, re-
spectively); 3) adjustment for confounding factors
(multiple factors including age and smoking; age alone
or along with factors other than smoking; none; with
scores of 2, 1, 0, respectively); 4) source and definition of
cancer diagnoses (based on chart or pathology review;
based on ICD code/death certificate or derived from
population register; none of the above; with scores of 2,
1, 0, respectively); and 5) representativeness of cases (in-
cludes the great majority of cases in a defined population
or a representative population-based sample; includes
only some cases in a population leading to an under-
representative sample, with scores of 1, 0, respectively).
Potential total scores ranged from 0 to 9. Studies scored
0–3, 4–6 and 7–9 were of low, medium and high quality.
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Final consistency of scores was achieved through
consensus.
Statistical analysis
The STATA, version 12.0 (StataCorp, College Station,
TX) was used to perform the analyses. We made no dis-
tinction between varying measures of association (SIR/
SER, OR or RR) reported in different studies and used
OR for all the studies. The pooled ORs with correspond-
ing 95 % CIs were calculated with Der Simonian and
Laird random-effects model [14]. Heterogeneity was
assessed using Cochran’s Q and I2 statistics, the percent-
ages of I2 around 25, 50 and 75 % mean low, medium
and high heterogeneity, respectively [15]. Subgroup ana-
lyses and sensitivity analyses were conducted to evaluate
sources of heterogeneity. Subgroup analyses were done
according to temporal relationship, gender and geo-
graphic region, respectively. Publication bias was evalu-
ated using Begg rank correlation test and the Egger
regression asymmetry test [16, 17].
Results
Search results and study characteristics
Twenty-four articles fulfilled our inclusion criteria and
were included in our meta-analysis with a total number
of 292,275 PD patients (Fig. 1). Among the 24 studies
there were 16 cohort studies [1–6, 10, 18–26], six case
control studies [27–32] and two cross-section studies
[33, 34]. Nine of the studies also provided information
on non-melanoma skin cancers and PD [3, 5, 10, 18, 19,
23, 27–29], and one study [33] only provided the risk of
skin cancers in PD patients. Most of the studies were
conducted in Europe and North America, only two stud-
ies were conducted in Asia [4, 26], and one study in
Oceania [31].
Association between melanoma and PD according to
temporal relationship
A total of 22 studies were included in the analysis, we
divided all the 22 studies into three subgroups according
to temporal relationship (study design), including “PD
Fig. 1 Flow diagram: Risk estimates on the association between PD and melanoma
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diagnosis preceding melanoma (cohort studies)” with 14
studies [1–6, 10, 19–22, 24–26], “melanoma preceding
PD diagnosis (case–control studies)” with nine studies
[3, 23, 24, 27–32] and “co-occurrence of PD and melan-
oma (cross-sectional studies)” with only one study [34].
Two studies provided data separately for melanoma be-
fore and after PD diagnosis [3, 24]. As shown in Fig. 2,
the overall pooled OR was 1.83 (95 % CI 1.46–2.30),
however, there was a significant heterogeneity across
studies (I2 = 82.4 %, PQ < 0.001). Subgroup analysis
showed that the pooled OR for “melanoma preceding
PD diagnosis” group was 1.09 (95 % CI 0.78–1.54), with
evidence of moderate heterogeneity (I2 = 58.1 %, PQ =
0.014). People with PD had increased risks (OR 2.43,
95 % CI 1.77–3.22) of melanoma compared with those
without PD as shown in the “PD diagnosis preceding
melanoma” group, with a significant heterogeneity
across studies (I2 = 87.8 %, PQ < 0.001). Only one study
reported the co-occurrence of PD and melanoma and
the OR was 1.83 (95 % CI 0.98–3.40). We examined the
source of heterogeneity by excluding the study of poor
quality [23]. After excluding this study from the analysis,
the pooled OR appeared significantly stronger (OR 1.93,
95 % CI 1.54–2.42), but the heterogeneity was still high
(I2 = 82.0 %, PQ < 0.001). When we further exclude the
study that reported the highest OR (OR 20.90) [25] and
the study that reported the lowest OR (OR 0.48) [31],
the pooled OR was 1.80 (95 % CI 1.52–2.14), and the
heterogeneity was reduced by nearly 22 % (I2 = 64.5 %,
PQ < 0.001). In detail, the heterogeneity in “melanoma
preceding PD diagnosis” group was completely elimi-
nated (I2 < 0.1 %, PQ = 0.999), while the heterogeneity in
“PD diagnosis preceding melanoma” group was signifi-
cant (I2 = 78.4 %, PQ < 0.001). To further examine the
source of heterogeneity across studies in “PD diagnosis
preceding melanoma” group, we did subgroup analysis
by geographic region (see the following).
Geographic region-specific analysis
In the subgroup analysis by geographic region (Fig. 3),
the overall pooled OR were 2.01 (95 % CI 1.57–2.57),
with high heterogeneity (I2 = 78.4 %, PQ < 0.001). Most
Fig. 2 Association between melanoma and PD according to temporal relationship. Subtotal = pooled odds ratios (ORs) within each subcategory.
Overall = pooled OR for all studies. Squares indicate study specific ORs; error bars indicate 95 % confidence intervals (CIs); diamonds indicate ORs
and 95 % CIs from pooled analyses
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of studies were done in Europe and North America, the
pooled OR for Europe was 1.51 (95 % CI 1.24–1.85) with
medium heterogeneity (I2 = 63.3 %, PQ = 0.018) and 2.69
for North America (95 % CI 1.77–4.08) with relatively
lower heterogeneity (I2 = 50.3 %, PQ = 0.09). Both Israel
(OR 4.40, 95 % CI 2.57–7.52) and Taiwan (OR 2.11,
95 % CI 0.21–21.25) only had one study.
Gender-specific analysis
In the subgroup analysis by gender, we included 9 stud-
ies for men [2, 5, 19, 21, 22, 24, 28–30] and 7 studies for
women [2, 5, 19, 22, 24, 28, 29]. In men, one study pro-
vided data separately for melanoma before and after PD
diagnosis [24]. Our results (Fig. 4) showed that the asso-
ciation between melanoma and PD was similar in both
men (OR 1.64, 95 % CI 1.27–2.13) and women (OR 1.38,
95 % CI 1.04–1.82), with evidence of moderate hetero-
geneity (I2 = 40.0 %, PQ = 0.045).
Non-melanoma skin cancers and PD
We included 10 studies [3, 5, 10, 18, 19, 23, 27–29, 33]
that provided information on non-melanoma skin can-
cers and PD (Fig. 5). Two studies provided the ORs both
before and after PD [3, 23]. One study provided only
gender-specific ORs [29]. The cumulative estimated risk
associated with non-melanoma skin cancers was 1.20
(95 % CI 1.11–1.29) with evidence of moderate hetero-
geneity (I2 = 41.9 %, PQ = 0.056). After excluding the
study of low quality [23], the overall pooled OR was 1.25
(95 % CI 1.19–1.32) and the heterogeneity was com-
pletely eliminated (I2 < 0.1 %, PQ = 0.713).
Evaluation for publication bias
The publication bias was detected from results of Begg
test and showed no significant evidence for bias (P =
0.503). The Egger test also did not show significant pub-
lication bias (P = 0.125).
Discussion
Parkinson’s disease (PD) is a neurodegenerative disorder,
characterized by depletion of dopamine in the striatum
and loss of melanin-positive, dopaminergic neurons in the
substantia nigra pars compacta (SNpc) [35, 36]. On the
other hand, cancer is a large group of diseases, character-
ized by uncontrolled growth of cells and the ability of me-
tastasis. Although PD and cancer seem to drive the cells
to different outcomes, that is either degeneration or over-
proliferation, the association between PD and cancer has
Fig. 3 Association between melanoma and PD according to geographic region. Subtotal = pooled odds ratios (ORs) within each subcategory.
Overall = pooled OR for all studies. Squares indicate study specific ORs; error bars indicate 95 % confidence intervals (CIs); diamonds indicate ORs
and 95 % CIs from pooled analyses
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been supported by plenty of epidemiologic studies, which
have shown that the incidences of most cancers are lower
in PD patients compared with controls [1–3]. However,
the incidence of melanoma is strikingly higher in pa-
tients with PD than that in general population [4–6].
The underlying mechanism that link PD with cancer
is not clear, but it has aroused lots of interests.
The results of our meta-analysis show a definite asso-
ciation between PD and melanoma. Since studies in-
cluded were of different study design, the heterogeneity
across studies was high. Subgroup analysis by study de-
sign reduced some part of heterogeneity and the hetero-
geneity further decreased after subgroup analysis by
geographic region. The result that risk of melanoma in
PD patients is significantly higher than that in controls
is in agreement with the result of previous meta-analysis
[37]. We involved more eligible evidences and carefully
assessed the quality of evidences which made the results
much more confirmed and we also added comparison
between different regions in the risk of melanoma. Pos-
sible mechanisms of the close association between PD
and melanoma are as follows.
Melanin is the primary determinant of skin and hair
color in human and more melanin pigment means darker
in skin color. Melanin exists in neurons within SN is
termed as “neuromelanin”; it is a protective factor that can
save neurons from oxidative stress. Abnormalities in mel-
anin can cause various skin cancers, including melanoma,
while PD is correlated with abnormalities in neuromela-
nin, it suggests that PD closely links to melanoma through
melanin [38]. Previous studies show melanin can re-
duce the susceptibility of skin to develop into melanoma
[39, 40]. However, decreased level of neuromelanin in SN
is associated with increased susceptibility of the neurons
to oxidative stress and impaired motor functions [41, 42].
Thus, melanin acts as a key connection between PD and
melanoma.
As the synthesis of dopamine and melanin share bio-
medical pathways and some case reports have found PD
patients developed local melanoma after initiation of L-
dopa therapy [7, 43-45], it is plausible that some scholars
link the high prevalence of melanoma in PD to L-dopa
therapy [46]. However, findings from recent clinical and
epidemiologic studies suggest that the link between L-
dopa therapy and melanoma was coincidental rather than
causal [10, 20]; it is PD that increases the risk of melan-
oma rather than L-dopa therapy. However, to get reliable
results we need to do meta-analysis, but it was impossible
yet since there were only two observational studies evalu-
ating the association between use of L-dopa and the
Fig. 4 Association between melanoma and PD according to gender. Subtotal = pooled odds ratios (ORs) within each subcategory. Overall =
pooled OR for all studies. Squares indicate study specific ORs; error bars indicate 95 % confidence intervals (CIs); diamonds indicate ORs and 95 %
CIs from pooled analyses
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incidences of melanoma in PD [10, 20]. Opponents argue
that melanocytes have not been shown to be able to in-
corporate external L-dopa. In addition, it has been shown
that dopamine is toxic for melanocytes in vitro [47]. Fur-
thermore, the increased rate of melanoma before the diag-
nosis of PD weakens the hypothesis that melanoma
may be induced by the treatment of PD [28]. On the
other hand, we found that PD may also increase the
risk of non-melanoma skin cancers [18, 19, 28]. The
association between PD and non-melanoma skin can-
cers also supports the conclusion of L-dopa as a
causal factor, unless the biochemical pathway includ-
ing L-dopa is common to all types of skin cancer.
Other anti-Parkinsonian drugs, such as selegiline and
CEP-1347, are also found to have no influence on the
association between PD and melanoma [20, 25].
Another potential explanation is that PD and mel-
anoma have genetic correlation. PD is characterized
by genetic susceptibility to environmental toxins due
to decreased enzymatic detoxification [48, 49]. Lack
of expression of enzymes encoded by GSTM1 can
lead to death of neurons related to PD [50-52]. In
addition, CYP2D6 polymorphism and VDR poly-
morphism also play important roles in the pathogen-
esis of PD [51, 53, 54]. Considering that high
frequency of polymorphisms of CYP2D6 or the poly-
morphism of VDR, and null for GSTM1 gene in mel-
anoma patients [55-57], it is plausible that changes in
GSTM1, CYP2D6 and VDR genes may increase the
risk for both PD and melanoma. Furthermore, some
PD-related genes, such as Parkin [58, 59], alpha-
synuclein [60, 61], LRRK2 [62, 63] and DJ-1 [64, 65],
were also found to play critical roles in the pathogen-
esis of melanoma. To sum up, mutations of those
genes can increase the risk of both PD and melan-
oma. However, scholars have found recently that the
LRRK2 G2019S mutation carriers had statistically sig-
nificant increased risks for non-skin cancers and there
was no association with melanoma [66]. Thus, to get
reliable results we need more studies focusing on the
Fig. 5 Association between non-melanoma skin cancers and PD. Subtotal = pooled odds ratios (ORs) within each subcategory. Overall = pooled
OR for all studies. Squares indicate study specific ORs; error bars indicate 95 % confidence intervals (CIs); diamonds indicate ORs and 95 % CIs
from pooled analyses
Huang et al. Translational Neurodegeneration  (2015) 4:21 Page 7 of 10
association between gene polymorphism and the risk
of melanoma in PD to allow for meta-analysis.
In addition, autophagy deficits have been linked to
neurodegenerative disease, such as PD, causing problems
in the clearance of injured mitochondria and aggregated
proteins [67, 68], whereas autophagy is also suppressed
in melanoma [69, 70]. Defective autophagy can promote
melanoma initiation and progression by causing im-
paired antigen presentation and melanoma immune es-
cape. Thus, reduction of autophagy plays an important
role both in PD and in melanoma. Whether PD links to
melanoma through defective autophagy still needs much
more direct evidences.
As to the risk factors of the development of melanoma,
previous meta-analysis have shown family history of mel-
anoma, high density of freckles, light skin color and fair
hair color as major risk factors for melanoma [71]. White
population is considered to have higher prevalence of mel-
anoma than the dark population. However, since studies
are mainly from Europe and North America, it is impos-
sible to evaluate the correlation between race and the risk
of developing melanoma in PD. More observational stud-
ies focusing on the association between PD and melanoma
from other race are needed. In addition, with regard to
geographic region, increased risk of melanoma in PD was
found both in Europe (1.51 times) and in North America
(2.69 times). The frequency of melanoma seems to be
lower in Europe than in North America, it may be due to
the following reasons. In Europe, melanoma incidence
varies among north/south and east/west regions with
Northern Europe gaining the most profoundly increase in
melanoma incidence. Variations in Europe could be ex-
plained by differences in skin phenotype as well as in sun-
exposure behaviors. Also it may be in part due to differ-
ences in case reporting and registration. Only half of
European countries have good quality cancer registries,
leading to the possibility of melanoma being under-
reported in certain countries.
We also performed gender-specific meta-analysis since
incidence of melanoma had been shown to be lower in
women than men [12]. However, our results show that
the connection between PD and melanoma is similar in
both men and women, that is, increased risk of melan-
oma in PD was found both in males and females.
We found that PD patients had slightly increased risk
of non-melanoma skin cancers than general population
(OR 1.20, 95 % CI 1.11–1.29). After excluding the study
of low quality [23], the heterogeneity was completely
eliminated and no significant change was found in OR
(1.25, 95 % CI 1.19–1.32). However, the results of a pre-
vious meta-analysis [37] indicated that there was no as-
sociation between PD and non-melanoma skin cancers
(OR 1.11, 95 % CI 0.94–1.30). Our results only indicate
a possible association between non-melanoma skin
cancers and PD. These conflicting results must be re-
solved by including more reliable studies into meta-
analysis in the future. In addition, we found OR for non-
melanoma in PD was only 1.2; there was no significant
increase. One of the common causative factor for melan-
oma and non-melanoma skin cancers is long-term sun
exposure, it may be hypothesized that PD patients are
more sensitive to sun-exposure-induced skin lesions.
The increased frequency of non-melanoma in PD may
be due to a disease-specific susceptibility. However,
melanoma occurs at a higher frequency in PD patients
than non-melanoma skin cancers, it seemed that be-
sides sun-exposure as a common risk factor, the shared
biochemical pathways between the synthesis of both
dopamine and melanin made PD patients more likely
to develop melanoma. In the future, it is necessary to
see the difference in the risk factors between PD pa-
tients who developed melanoma and those who devel-
oped non-melanoma skin cancers.
Limitations
There were several limitations in our meta-analysis.
Firstly, most of the studies included were not focusing
on the association between PD and melanoma; melan-
oma was mostly evaluated along with other cancers.
Moreover, the number of cases with both PD and melan-
oma is usually small. Lastly, the majority of these studies
did not collect enough data on risk factors for us to ex-
plore potential explanations.
Conclusion
In conclusion, melanoma occurs more frequently among
patients with PD. Most of the evidences were of high qual-
ity, and the conclusion was robust. According to the refer-
ences, most scholars consider that there are no strong
evidences supporting the idea that dopaminergic therapy
shall increase the risk of melanoma in PD. However, reli-
able conclusion will need more studies focusing on the as-
sociation between L-dopa use and the development of
melanoma in PD. The positive association between PD
and melanoma may be explained by pigmentation changes
in melanin and/or melanin synthesis enzyme, genetic cor-
relations or autophagy deficits.
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